CD8A and melanoma: Notably, NLRC4 can promote cytokine and chemokine release in TAMs and amplify protective IFN-γ-producing CD4+ and CD8+ T cells, thereby diminishing tumor growth in melanoma independent of inflammasome assembly (76).